Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big pharma is set to keep signing bigger deals in 2024

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 05, 2024 10:46am

90 Views

Post# 36023821

RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

May 02, 2024 - According to the law firm of Morgan Lewis of Boston, MA., "Biopharma dealmaking could accelerate in 2024 and onwards because the industry is now reaching the much-anticipated “patent cliff” where several pharma companies have major blockbusters that are going to go off patent protection relatively quickly.

The sector retains more than $1.37 trillion in available capital for M&A, leaving a lot of “dry powder” on the sidelines for M&A activity. It is important to note that M&A in pharma tends to be driven more by strategic priority than depressed value for a particular company. So even if a price for a company is low, an acquisition will likely depend on whether that company fits into the strategic goals of the buyer.

In 2024, we expect M&A will more closely resemble prior years with a total deal value in the $225 billion to $275 billion range across all subsectors of the life sciences industry. We continue to expect that deals in the $5 billion to $15 billion range will be the market sweet spot but see the potential for one or more deals in the $20 billion to $40 billion range before year-end."

https://www.morganlewis.com/pubs/2024/05/trends-and-tips-for-navigating-life-sciences-m-a-in-2024

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects